Mulpleo (Lusutrombopag)

Lusutrombopag binds to the c‑Mpl (thrombopoietin) receptor on megakaryocyte precursors, activating signaling pathways that stimulate megakaryocyte growth and maturation, which in turn raises the production of platelets in the bloodstream.

The dosage of Mulpleo is individualized by a qualified prescriber based on the patient’s platelet count, liver function, and procedural timing. The prescribing information provides detailed guidance, and clinicians determine the appropriate regimen for each case.

Safety data for lusutrombopag in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by the treating physician.

To request Mulpleo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mulpleo (lusutrombopag) is a small‑molecule oral thrombopoietin receptor agonist, whereas alternatives such as avatrombopag or injectable agents like romiplostim have different routes, dosing schedules, and metabolic pathways. Choice depends on patient preference, liver function, drug‑interaction profile, and clinical setting.

Mulpleo tablets should be stored at ambient temperature below 25 °C, in the original packaging, protected from moisture and direct sunlight. This ensures chemical stability and maintains potency throughout the shelf life.

Mulpleo is taken orally as a tablet, usually with water. The exact timing relative to the planned invasive procedure is determined by the prescriber, who will also advise on any necessary fasting or concomitant medication adjustments.

The most serious risks include thrombotic events such as portal vein thrombosis and hepatic decompensation. Patients should be monitored for signs of abnormal clot formation, worsening liver function, or unexpected bleeding, and therapy should be stopped if severe adverse events occur.

Mulpleo is contraindicated in patients with active thrombosis, uncontrolled severe liver disease, or known hypersensitivity to lusutrombopag or any tablet excipients. It should also be avoided in individuals for whom the risk of platelet over‑production outweighs the clinical benefit.